In a 4.3-year follow-up study, few asymptomatic patients with preclinical left ventricular diastolic dysfunction (LVDD) progressed to heart failure with preserved ejection fraction (HFpEF), with a ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Among patients with heart failure with preserved ejection fraction, long-term treatment with the medication spironolactone improved left ventricular diastolic function but did not affect maximal ...

—A recent study used transcriptomic analysis to identify specific clinical features of HFpEF, with the ultimate goal of introducing improved, personalized therapies. A transcriptome analysis has ...

Please provide your email address to receive an email when new articles are posted on . An AI algorithm for detection of grade 3 diastolic dysfunction received a breakthrough device designation from ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

My patients’ concerns about heart failure are usually, “What is my prognosis?” “What are the treatments, like medication and surgery, that are available to me?” But some people will ask me for their ...

Sudden cardiac death is a common cause of death in patients with reduced systolic ejection function. As part of a long-term observational study, MedUni Vienna researchers from the Division of ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...